Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania Dr. Andrew Wells is Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine, […]
Joseph Hollander Chair in Pediatric Rheumatology, Children’s Hospital of Philadelphia Chief, Division of Rheumatology, Children’s Hospital of Philadelphia Assistant Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania Dr. […]
Paul B. Beeson Professor of Medicine (Rheumatology), Department of Internal Medicine (Rheumatology, Allergy & Immunology), Yale School of Medicine, Yale University Professor of Immunobiology, Department of Immunobiology, Yale School of […]
Identifying a novel molecular regulator of tolerogenic dendritic cell function, this project uncovers how its loss triggers spontaneous multiorgan autoimmunity and exacerbates lupus — revealing a clinically relevant pathway in immune tolerance.
A self-replicating RNA platform delivers anti-inflammatory cytokines directly to the airways, offering targeted local immune suppression without systemic toxicity — a mechanistically distinct approach to treating lupus lung disease.
Developing a bioavailable DNAseIL3 biologic to degrade pathogenic autoantibodies and treat lupus and related autoimmune diseases.
Repurposing nuclear-penetrating autoantibodies from lupus and scleroderma patients as potent, safe inhibitors of pathogenic NETosis.
Identifying DNA methylation signatures in blood and urine as non-invasive biomarkers to classify lupus nephritis and guide treatment without repeated biopsies.
Exploiting a newly discovered PD-1 dimerization mechanism, this project engineers monoclonal antibodies to more effectively suppress overactive T cells — offering a novel immune tolerance strategy for autoimmune diseases.
Developing CART4-34, a novel CAR T cell therapy that selectively eliminates IGHV4-34+ pathogenic B cells in lupus while sparing healthy B cells and avoiding broad immunosuppression.
